Last reviewed · How we verify

NCT06102343

Safety and Efficacy Investigation on the Effects of ClearSkin Non-ablative ER:Glass 1540nm Laser Module in the Treatment of Acne Scars.

Status unknown NA Last updated 26 October 2023
What this trial tests

NA trial testing Alma Harmony in Acne Scars - Mixed Atrophic and Hypertrophic in 41 participants. Status unknown.

Timeline
1 January 2024
Primary endpoint
1 January 2025
1 January 2025

Quick facts

Lead sponsorAlma Lasers
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment41
Start date1 January 2024
Primary completion1 January 2025
Estimated completion1 January 2025
Sites1 location across Portugal

Drugs / interventions tested

Conditions studied

Sponsor

Alma Lasers

Who can join

Adults 18 to 50, any sex, with Acne Scars - Mixed Atrophic and Hypertrophic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The ClearSkin module, Er: Glass 1540nm, is largely used in the treatment of acne vulgaris and acne scars. The non-ablative ER:Glass 1540 nm laser deeply penetrates the skin, causing thermal damage to the sebaceous glands, destroying P. acnes bacteria and reducing sebum production, while leaving the epidermis intact. The integrated vacuum mechanism extracts accumulated sebaceous material from the pores, while contact cooling protects the skin, reducing pain and allowing for safer and more effective treatment of the sebaceous glands within the dermis. Based on this background, the investigators have considered a pilot study aimed at assessing the efficacy and safety of the ClearSkin Module in treating subjects with facial acne scars.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acne Scars - Mixed Atrophic and Hypertrophic

Currently open trials in the same condition.

Other Alma Lasers trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06102343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing